Table 1 Evaluation and follow-up of HT-1 patients identified by newborn screening
Evaluation | Initiation of therapy (baseline) | First year of life | From 1 year to 5 years of age | After 5 years of age | |||
---|---|---|---|---|---|---|---|
Monthly | Every 3 months | Every 3 months | Every 6 months | Yearly | |||
HT-1 markers | |||||||
Blood succinylacetonea (plasma/ blood on filter paper) | x | xb | x | Every 6 months | |||
Urine succinylacetone (only if blood is not available) | x | x | x | Every 6 months | |||
Blood NTBC concentrationa | x | x | Every 6 months | ||||
Plasma amino acids (plasma/blood on filter paper) | x | xb | x | Every 6 monthsc | |||
Laboratories for HT-1 monitoring | |||||||
CBC: hemoglobin, hematocrit, WBC, platelet count | x | x | x | Yearly | |||
Liver evaluation | |||||||
Serum AFP concentration | x | x | x | Every 6 monthsd | |||
PT | x | xe | x | Yearly | |||
PTT | x | xe | x | Yearly | |||
ALT/AST | x | xe | x | Yearly | |||
Imaging: CT or MRI (with contrast) or ultrasoundf,g | x | xc | Yearlyc | ||||
Renal studies | |||||||
Renal imaging (ultrasound)h | x | ||||||
Blood chemistries: bicarbonate, BUN, creatinine | x | x | Yearly | ||||
Blood calcium and phosphate | x | x | Yearly | ||||
Urine analysis | x | ||||||
Standard dietary management laboratories: if not included above, see text for more information | |||||||
Developmental evaluation/ neuropsychology assessment | Before school age | ||||||
Ophthalmology: slit-lamp examination | When symptomatic or at increased risk (see text for more information) |